ASTELLAS PHARMA US, INC. for ASTELLAS PHARMA US, INC.
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Copyright/Patent/Trademark CPT
Issues related to various patent reform bills (H.R.9, S.632, S.1137).
Foreign entity interest: Astellas Pharma, Inc. based in Tokyo, Japan and as identified in our Lobbying Registration, has an interest as a pharmaceutical company in all of the issues with respect to which Astellas Pharma US has lobbied and listed above.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MELISSA WIER BANASHAK | — |
| MARY LACEY REUTHER | — |
Health Issues HCR
Issues related to the implementation of healthcare reform (P.L.111-148, P.L.111-152); Issues related to oral chemotherapy in The Cancer Drug Coverage Parity Act (S.1566, H.R.2739); The 21st Century Cures Act (H.R.6).
Foreign entity interest: Astellas Pharma, Inc. based in Tokyo, Japan and as identified in our Lobbying Registration, has an interest as a pharmaceutical company in all of the issues with respect to which Astellas Pharma US has lobbied and listed above.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MELISSA WIER BANASHAK | — |
| MARY LACEY REUTHER | — |
Medicare/Medicaid MMM
Issues related to the implementation of health care reform (P.L.111-148, P.L.111-152); Issues related to the Medicare hospital outpatient issues (H.R.1178, S.1466); Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms Act of 2015 (DISARM) (H.R.512)
Foreign entity interest: Astellas Pharma, Inc. based in Tokyo, Japan and as identified in our Lobbying Registration, has an interest as a pharmaceutical company in all of the issues with respect to which Astellas Pharma US has lobbied and listed above.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MELISSA WIER BANASHAK | — |
| MARY LACEY REUTHER | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.